The Unmet Need for a Biomarker to Support Imaging
Professor Mark Emberton OBE, University College London, on his study that aims to improve the current prostate specific antigen (PSA)/biopsy risk stratification for prostate cancer (CaP) and develop a new image-based method with biomarkers like the MiCheck® Prostate for determining high/low risk PCa in men.
Expert Opinion on Need for Biomarker Panels in Biopsy Decisions
Neal D. Shore, MD, FACS presented abstract 229 regarding the current need for a more accurate test to identify patients for prostate biopsy at the 2022 ASCO Genitourinary Cancers Symposium.